Cancer/Tumor Profiling Market by Application (Clinical, Research), Technology (Immunoassay, Hybridization (PCR, In Situ Hybridization, DNA/RNA Microarray), NGS, Mass Spectrometry), Cancer Type (Breast, Lung, Prostate, Colorectal) - Global Forecast to 2022

Global cancer profiling market is projected to reach USD 8.74 Billion in 2022 from USD 4.75 Billion in 2016 at a CAGR of 10.7%. The base year considered for the study is 2016, and the forecast for the market size is provided for the period between 2017 and 2022.

Growth in the cancer profiling market is driven by the increasing number of cancer cases, growing utility of biomarkers in tumor profiling, and availability of funding for cancer research. In addition, the introduction and adoption of point-of-care diagnostic tests and development of personalized medicine are expected to offer growth opportunities for manufacturers of cancer/tumor profiling solutions. However, high capital investments and low benefit ratio of biomarkers are restraining the growth of this market

Objectives of the Study

• To define, describe, and forecast the cancer/tumor profiling market on the basis of application, technology, cancer type, and region
• To provide a detailed information regarding the major factors influencing the growth of the market (drivers, restraints, opportunities, and challenges)
• To strategically analyze micromarkets with respect to individual growth trends, prospects, and contribution to the total market
• To analyze the opportunities in the market for stakeholders and details of a competitive landscape for market leaders
• To forecasting the revenue of market segments with respect to four main geographies (along with countries), namely, North America, Europe, Asia Pacific, and the RoW
• To profile key players and comprehensively analyze their market shares and core competencies
• To track and analyze competitive developments such as collaborations, new product developments, product enhancements, and R&D activities in the cancer/tumor profiling market

Research Methodology

Top-down and bottom-up approaches were used to validate the size of the global cancer profiling market and estimate the size of various other dependent submarkets. Major players in the market were identified through secondary research and their market revenues were determined through primary and secondary research. Secondary research included the study of the annual and financial reports of top market players, white papers, medical journals, certified publications, articles from recognized authors, directories, and databases, whereas primary research included extensive interviews with key opinion leaders such as CEOs, directors, and marketing executives. The percentage splits, shares, and breakdowns of the segments were determined using secondary sources and verified through primary sources. This data is consolidated and added to detailed inputs and analysis from MarketsandMarkets and presented in this report.

To know about the assumptions considered for the study, download the pdf brochure

 The cancer profiling market is dominated by established players such as Illumina (US), QIAGEN (Netherlands), NeoGenomics Laboratories (US), HTG Molecular Diagnostic (US), Genomic Health (US), Caris Life Sciences (US), Helomics Corporation (US), NanoString Technologies (US), Oxford Gene Technology (UK), and RiboMed Biotechnologies (US).

Target Audience:

• Hospitals and clinics
• Research institutes and clinical research organizations (CROs)
• Market research and consulting firms
• Authorities framing reimbursement policies for use of cancer diagnostics
• Companies offering platforms/technologies for cancer diagnosis
• Market research and consulting firms

Scope of the Report

This research report categorizes the global market on the basis of technology, cancer type, application, and region

Global Cancer Profiling Market, by Application

• Clinical Applications
• Research Applications

Global Cancer Profiling Market, by Technology

• Immunoassays
• Hybridization
• Next-generation Sequencing
• Mass Spectroscopy
• Other Technologies (Pyrosequencing and Sanger Sequencing)

Global Cancer Profiling Market, by Cancer Type

• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Prostate Cancer
• Melanoma Cancer
• Other Cancer Types (Non-Hodgkin’s Lymphoma, Melanoma, Leukemia, Thyroid, Bladder, and Kidney)

Global Cancer Profiling Market, by Region

• North America
  • US
  • Canada
• Europe
• Asia Pacific
• Rest of the World (RoW)

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:

Geographic Analysis

• Country-wise analysis of the European and Asia Pacific cancer profiling market

Company Information

• Detailed analysis and profiling of additional market players (Up to 5)

Table of Contents

1 Introduction (Page No. - 13)
    1.1 Objectives of the Study
    1.2 Market Definition
           1.2.1 Markets Covered
    1.3 Years Considered for the Study
    1.4 Currency
    1.5 Limitations
    1.6 Stakeholders

2 Research Methodology (Page No. - 16)
    2.1 Market Size Estimation
    2.2 Market Breakdown and Data Triangulation
           2.2.1 Key Data From Secondary Sources
           2.2.2 Key Data From Primary Sources
                    2.2.2.1 Key Industry Insights
           2.2.3 Assumptions for the Study
    2.3 Macroeconomic Factor Analysis
           2.3.1 Introduction
           2.3.2 Demand-Side Analysis
                    2.3.2.1 Healthcare Expenditure Pattern
           2.3.3 Supply-Side Analysis
                    2.3.3.1 Number of New Product Launches

3 Executive Summary (Page No. - 25)

4 Premium Insights (Page No. - 30)
    4.1 Cancer Profiling Market: Overview
    4.2 Geographic Analysis: Cancer Profiling Market, By Technology (2017)
    4.3 Cancer Profiling Market, By Application
    4.4 Cancer Profiling Market, By Hybridization Technology
    4.5 Geographical Snapshot of the Cancer Profiling Market

5 Market Overview (Page No. - 34)
    5.1 Introduction
    5.2 Market Dynamics
           5.2.1 Drivers
                    5.2.1.1 Increasing Number of New Cancer Cases
                    5.2.1.2 Increasing Utility of Biomarkers in Tumor Profiling
                    5.2.1.3 Availability of Funding for Cancer Research
           5.2.2 Restraints
                    5.2.2.1 High Capital Investments and Low Benefit Ratio for Biomarkers
                    5.2.2.2 Lack of Skilled Professionals and Infrastructure
           5.2.3 Opportunities
                    5.2.3.1 Point-Of-Care Diagnostic Tests
                    5.2.3.2 Increasing Demand for Personalized Medicine
           5.2.4 Challenge
                    5.2.4.1 Unclear Regulatory and Reimbursement Scenario

6 Cancer/Tumor Profiling Market, By Technology (Page No. - 42)
    6.1 Introduction
    6.2 Immunoassays
    6.3 Hybridization
           6.3.1 PCR
           6.3.2 In Situ Hybridization (ISH)
           6.3.3 DNA/RNA Microarray
    6.4 Next Generation Sequencing
    6.5 Mass Spectrometry
    6.6 Other Technologies

7 Cancer/Tumor Profiling Market, By Cancer Type (Page No. - 58)
    7.1 Introduction
    7.2 Breast Cancer
    7.3 Lung Cancer
    7.4 Colorectal Cancer
    7.5 Prostate Cancer
    7.6 Melanoma Cancer
    7.7 Others Cancer

8 Cancer/Tumor Profiling Market, By Application (Page No. - 67)
    8.1 Introduction
    8.2 Clinical Application
    8.3 Research Application

9 Cancer/Tumor Profiling Market, By Region (Page No. - 72)
    9.1 Introduction
    9.2 North America
           9.2.1 U.S.
           9.2.2 Canada
    9.3 Europe
    9.4 Asia-Pacific
    9.5 Rest of the World (RoW)

10 Competitive Landscape (Page No. - 93)
     10.1 Overview
     10.2 Battle for Market Share: Product Launch Was the Key Growth Strategy Adopted By Market Players Between 2013 and 2016
     10.3 Product Launches
     10.4 Agreements, Collaborations, and Partnerships
     10.5 Acquisitions
     10.6 Others Strategies

11 Company Profiles (Page No. - 98)
(Introduction, Products & Services, Strategy, & Analyst Insights, Developments, MnM View)*
     11.1 Introduction
     11.2 Illumina, Inc.
     11.3 Qiagen N.V.
     11.4 Neogenomics Laboratories, Inc.
     11.5 HTG Molecular Diagnostics, Inc.
     11.6 Genomic Health Inc.
     11.7 Caris Life Sciences
     11.8 Helomics Corporation
     11.9 Nanostring Technologies, Inc.
     11.10 Oxford Gene Technology
     11.11 Ribomed Biotechnologies, Inc.

*Details on Marketsandmarkets View, Introduction, Product & Services, Strategy, & Analyst Insights, New Developments Might Not Be Captured in Case of Unlisted Companies.

12 Appendix (Page No. - 141)
     12.1 Insights of Industry Experts
     12.2 Discussion Guide
     12.3 Other Developments
     12.4 Knowledge Store: Marketsandmarkets’ Subscription Portal
     12.5 Introducing RT: Real-Time Market Intelligence
     12.6 Available Customizations
     12.7 Related Reports
     12.8 Author Details

List of Tables (67 Tables)

Table 1 List of Fda-Approved Biomarkers for Different Types of Cancer
Table 2 National Institutes of Health (NIH) Spending, By Type of Cancer (Financial Year 2015)
Table 3 Cancer/Tumor Profiling Market Size, By Technology, 2015–2022 (USD Million)
Table 4 Hybridization Market for Cancer/Tumor Profiling, By Technology, 2015–2022 (USD Million)
Table 5 Global Immunoassays Market for Cancer/Tumor Profiling, By Region, 2015–2022 (USD Million)
Table 6 North America: Immunoassays Market for Cancer/Tumor Profiling, By Country, 2015–2022 (USD Million)
Table 7 Global Hybridization Market for Cancer/Tumor Profiling, By Region, 2015-2022 (USD Million)
Table 8 North America: Hybridization Market for Cancer/Tumor Profiling, By Country, 2015–2022 (USD Million)
Table 9 Global PCR Market for Cancer/Tumor Profiling, By Region, 2015–2022 (USD Million)
Table 10 North America: PCR Market for Cancer/Tumor Profiling, By Country, 2015–2022 (USD Million)
Table 11 Global In Situ Hybridization Market for Cancer/Tumor Profiling, By Region, 2015–2022 (USD Million)
Table 12 North America: In Situ Hybridization Market for Cancer/Tumor Profiling, By Country, 2015–2022 (USD Million)
Table 13 Global DNA/RNA Microarray Market for Cancer/Tumor Profiling, By Region, 2015–2022 (USD Million)
Table 14 North America: DNA/RNA Microarray Market for Cancer/Tumor Profiling, By Country, 2015–2022 (USD Million)
Table 15 Global Next-Generation Sequencing Market for Cancer/Tumor Profiling, By Region, 2015–2022 (USD Million)
Table 16 North America: Next-Generation Sequencing Market for Cancer/Tumor Profiling, By Country, 2015–2022 (USD Million)
Table 17 Global Mass Spectrometry Market for Cancer/Tumor Profiling, By Region, 2015–2022 (USD Million)
Table 18 North America: Mass Spectrometry Market for Cancer/Tumor Profiling, By Country, 2015–2022 (USD Million)
Table 19 Global Other Technologies Market for Cancer/Tumor Profiling, By Region, 2015–2022 (USD Million)
Table 20 North America: Other Technologies Market for Cancer/Tumor Profiling, By Country, 2015–2022 (USD Million)
Table 21 Global Cancer Profiling Market Size, By Cancer Type, 2015–2022 (USD Million)
Table 22 Global Breast Cancer Profiling Market Size, By Region, 2015–2022 (USD Million)
Table 23 North America Breast Cancer Profiling Market, By Country, 2015–2022 (USD Million)
Table 24 Global Lung Cancer Profiling Market, By Region, 2015–2022 (USD Million)
Table 25 North America Lung Cancer Profiling Market, By Country, 2015–2022 (USD Million)
Table 26 Global Colorectal Cancer Profiling Market, By Region, 2015–2022 (USD Million)
Table 27 North America Colorectal Cancer Profiling Market, By Country, 2015–2022 (USD Million)
Table 28 Global Prostate Cancer Profiling Market, By Region, 2015–2022 (USD Million)
Table 29 Global Melanom Cancer Profiling Market, By Region, 2015–2022 (USD Million)
Table 30 North America Melanoma Cancer Profiling Market, By Country, 2015–2022 (USD Million)
Table 31 Global Other Type of Cancer Profiling Market, By Region, 2015–2022 (USD Million)
Table 32 North America Other Type of Cancer Profiling Market By Country, 2015–2022 (USD Million)
Table 33 Cancer/Tumor Profiling Market Size, By Application, 2015–2022 (USD Million)
Table 34 Cancer Profiling Market for Clinical Application, By Region, 2015–2022 (USD Million)
Table 35 North America: Cancer/Tumor Profiling Market for Clinical Application, By Region, 2015–2022 (USD Million)
Table 36 Cancer Profiling Market for Resaerch Application, By Region, 2015–2022 (USD Million)
Table 37 North America: Cancer/Tumor Profiling Market for Resaerch Application, By Region, 2015–2022 (USD Million)
Table 38 Global Cancer Profiling Market, By Region, 2015–2022 (USD Million)
Table 39 North America: Cancer Profiling Market Size, By Country, 2015–2022 (USD Million)
Table 40 North America: Market Size, By Cancer Type, 2015–2022 (USD Million)
Table 41 North America: Market, By Technology, 2015–2022 (USD Million)
Table 42 North America: Hybridization Technology Market, By Type, 2015–2022 (USD Million)
Table 43 North America: Market, By Application, 2015–2022 (USD Million)
Table 44 US: Cancer Profiling Market, By Technology, 2015–2022 (USD Million)
Table 45 US: Hybridization Technology Market, By Type, 2015–2022 (USD Million)
Table 46 US: Market, By Application, 2015–2022 (USD Million)
Table 47 US: Cancer Profiling Market, By Cancer Type, 2015–2022 (USD Million)
Table 48 Canada: Cancer Profiling Market, By Technology, 2015–2022 (USD Million)
Table 49 Canada: Hybridization Technology Market, By Type, 2015–2022 (USD Million)
Table 50 Canada: Market, By Application, 2015–2022 (USD Million)
Table 51 Canada: Market, By Cancer Type, 2015–2022 (USD Million)
Table 52 Europe: Cancer Profiling Market, By Cancer Type, 2015–2022 (USD Million)
Table 53 Europe: Market, By Technology, 2015–2022 (USD Million)
Table 54 Europe: Hybridization Technology Market, By Type, 2015–2022 (USD Million)
Table 55 Europe: Market, By Application, 2015–2022 (USD Million)
Table 56 Asia-Pacific: Cancer Profiling Market, By Cancer Type, 2015–2022 (USD Million)
Table 57 Asia-Pacific: Cancer Profiling Market, By Technology, 2015–2022 (USD Million)
Table 58 Asia-Pacific: Hybridization Technology Market, By Type, 2015–2022 (USD Million)
Table 59 Asia-Pacific: Market, By Application, 2015–2022 (USD Million)
Table 60 RoW: Cancer Profiling Market, By Cancer Type, 2015–2022 (USD Million)
Table 61 RoW: Cancer Profiling Market, By Technology, 2015–2022 (USD Million)
Table 62 RoW: Hybridization Technology Market, By Type, 2015–2022 (USD Million)
Table 63 RoW: Cancer Profiling Market, By Application, 2015–2022 (USD Million)
Table 64 Product Launches, 2013–2016
Table 65 Agreements, Collaborations, and Partnerships, 2013–2016
Table 66 Acquisitions, 2013–2016
Table 67 Other Strategies, 2013–2016

List of Figures (32 Figures)

Figure 1 Research Design
Figure 2 Cancer/Tumor Profiling Market Top Down Approach
Figure 3 Cancer Profiling Market: Bottom Up Approach
Figure 4 Breakdown of Primary Interviews: By Company Type, Designation, and Region
Figure 5 Market Data Triangulation Methodology
Figure 6 Healthcare Expenditure Across Major Countries: 2000 vs 2014
Figure 7 Cancer/Tumor Profiling Market, By Cancer Type, 2017 vs 2022 (USD Million)
Figure 8 Cancer Profiling Market, By Technology, 2017 vs 2022 (USD Million)
Figure 9 Cancer/Tumor Profiling Market, By Hybridization Technology, 2017 vs 2022 (USD Million)
Figure 10 Cancer Profiling Market, By Application, 2017 vs 2022 (USD Million)
Figure 11 Geographical Snapshot of the Cancer/Tumor Profiling Market
Figure 12 Technology Advancement is A Major Driver for the Cancer Profiling Market Growth in 2017
Figure 13 Clinical Application Will Continue to Dominate the Cancer Profiling Market in 2022
Figure 14 PCR is Expected to Be the Fastest Growing Segment During Forecast Period
Figure 15 APAC Will Be the Fastest-Growing Market From 2017 to 2022
Figure 16 Cancer/Tumor Profiling Market: Drivers, Restraints, Opportunities, and Challenges
Figure 17 Increasing Number of New Cancer Cases Worldwide (2012 vs 2015 vs 2020)
Figure 18 New Cancer Cases, By Country (2012)
Figure 19 New Cancer Cases, By Country (2020)
Figure 20 Immunoassays Segment to Dominate the Market in the Forecast Period
Figure 21 Clinical Application Segment to Dominate the Market in the Forecast Period
Figure 22 Cancer Profiling Market: Geographic Snapshot (2017–2022)
Figure 23 North America Market Snapshot
Figure 24 Asia-Pacific Cancer Profiling Market Snapshot
Figure 25 Companies Majorly Pursued the Strategy of Product Launch Between 2013 and 2016
Figure 26 Geographic Revenue Mix of the Prominent Players in the Cancer Profiling Market
Figure 27 Company Snapshot: Illumina, Inc.
Figure 28 Company Snapshot: Qiagen N.V.
Figure 29 Company Snapshot: Neogenomics Laboratories, Inc.
Figure 30 Company Snapshot: HTG Molecular Diagnostics, Inc.
Figure 31 Company Snapshot: Genomic Health Inc.
Figure 32 Company Snapshot: Nanostring Technologies, Inc.

Global cancer profiling market is projected to reach USD 8.74 Billion in 2022 from USD 5.26 Billion in 2017 at CAGR of 10.7%. Growth in the cancer/tumor profiling market is driven by the increasing number of cancer cases, growing utility of biomarker in tumor profiling, and availability of funding for cancer research. In addition, the introduction and adoption of point-of-care diagnostic tests and development of personalized medicine are expected to offer growth opportunities for manufacturers of cancer/tumor profiling solutions. However, high capital investments and low benefit ratio of biomarkers are restraining the growth of this market.

In this report, the global cancer profiling market in this report is segmented by cancer type, application, technology, and region. On the basis of cancer type, the cancer type market is categorized into breast cancer, lung cancer, colorectal cancer, prostate cancer, melanoma, and other cancer types. In 2017, the breast cancer segment is expected to account for the largest share of the global cancer/tumor profiling market. The largest share of this segment is mainly attributed to the high prevalence of breast cancer over the last few years, increased awareness about breast cancer diagnosis, and increasing research focus on breast cancer.

On the basis of technology, the global cancer profiling market is broadly divided into immunoassays, hybridization, NGS, mass spectrometry, and other technologies. In 2017, the immunoassays segment is expected to account for the largest share of the cancer/tumor profiling technologies market. The high sensitivity and cost-effectiveness of these techniques as well as technological advancements in these immunoassays tests are factors that are expected to propel the growth of this market in the coming years. Furthermore, the hybridization technology is again divided on the basis of type which includes PCR, in-situ hybridization, and microarrays. The PCR segment is expected to account for the largest market share of hybridization technology in 2017. PCR is one of the most widely used technologies in the diagnostics market. This is primarily due to its ease of use, cost-effectiveness, quick turnaround time (4 to 6 hours), and easy availability of kits and reagents.

North America is expected to account for the largest share of the cancer/tumor profiling market in 2017. Asia Pacific is estimated to witness the highest growth during the forecast period. The Asia Pacific region is expected to register the highest CAGR in the forecast period. In recent years, the Asia Pacific market for cancer/tumor profiling has witnessed significant growth due to the rising incidence of cancer, increasing demand for better healthcare services in developing economies such as India and China, rising number of contract research organizations (CROs), and increasing focus of international players on emerging markets.

Major players operating in the cancer profiling market include Illumina (US), QIAGEN (Netherlands), NeoGenomics Laboratories (US), HTG Molecular Diagnostic (US), and Genomic Health (US). These players focus on inorganic strategies such as acquisitions, agreements, and collaborations as well as organic strategies such as product launches and expansions to sustain their growth in the cancer/tumor profiling market.

To speak to our analyst for a discussion on the above findings, click Speak to Analyst